Literature DB >> 21382667

Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach.

Amanda J Abraham1, Traci Rieckmann2, Thomas McNulty3, Anne E Kovas2, Paul M Roman4.   

Abstract

Alcohol use disorders (AUDs) continue to be one of the most pervasive and costly of the substance use disorders (SUDs). Despite evidence of clinical effectiveness, adoption of medications for the treatment of AUDs is suboptimal. Low rates of AUD medication adoption have been explained by characteristics of both treatment organizations and individual counselor's attitudes and behaviors. However, few studies have simultaneously examined the impact of organizational-level and counselor-level characteristics on counselor perceptions of EBPs. To address this gap in the literature, we use data from a national sample of 1178 counselors employed in 209 privately funded treatment organizations to examine the effects of organizational and individual counselor characteristics on counselor attitudes toward tablet and injectable naltrexone. Results of hierarchical linear modeling (HLM) show that organizational characteristics (use of tablet/injectable naltrexone in the program, 12-step orientation) were associated with counselor perceptions of naltrexone. Net of organizational characteristics, several counselor level characteristics were associated with attitudes toward tablet and injectable naltrexone including gender, tenure in the field, recovery status, percentage of AUD patients, and receipt of medication-specific training. These findings reveal that counselor receptiveness toward naltrexone is shaped in part by the organizational context in which counselors are embedded.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21382667      PMCID: PMC3070850          DOI: 10.1016/j.addbeh.2011.01.030

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  37 in total

1.  Can the national addiction treatment infrastructure support the public's demand for quality care?

Authors:  A Thomas McLellan; Deni Carise; Herbert D Kleber
Journal:  J Subst Abuse Treat       Date:  2003-09

2.  Practitioner attitudes toward evidence-based practice: themes and challenges.

Authors:  Timothy D Nelson; Ric G Steele; Jennifer A Mize
Journal:  Adm Policy Ment Health       Date:  2006-05

3.  The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters.

Authors:  Hannah K Knudsen; Lori J Ducharme; Paul M Roman
Journal:  Drug Alcohol Depend       Date:  2006-09-12       Impact factor: 4.492

4.  Counselor assessments of training and adoption barriers.

Authors:  Norma G Bartholomew; George W Joe; Grace A Rowan-Szal; D Dwayne Simpson
Journal:  J Subst Abuse Treat       Date:  2007-04-16

5.  Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.

Authors:  Stephanie S O'Malley; James C Garbutt; David R Gastfriend; Qunming Dong; Henry R Kranzler
Journal:  J Clin Psychopharmacol       Date:  2007-10       Impact factor: 3.153

6.  Why are recovering substance abuse counselors paid less?

Authors:  Todd A Olmstead; J Aaron Johnson; Paul M Roman; Jody L Sindelar
Journal:  Subst Abus       Date:  2007-03       Impact factor: 3.716

7.  Extended-release naltrexone for treatment of alcohol dependence in primary care.

Authors:  Joshua D Lee; Ellie Grossman; Danae DiRocco; Andrea Truncali; Kathleen Hanley; David Stevens; John Rotrosen; Marc N Gourevitch
Journal:  J Subst Abuse Treat       Date:  2010-04-02

8.  What role does measuring medication compliance play in evaluating the efficacy of naltrexone?

Authors:  Alicia M Baros; Patricia K Latham; Darlene H Moak; Konstantin Voronin; Raymond F Anton
Journal:  Alcohol Clin Exp Res       Date:  2007-04       Impact factor: 3.455

9.  Naltrexone and alcohol dependence. Role of subject compliance.

Authors:  J R Volpicelli; K C Rhines; J S Rhines; L A Volpicelli; A I Alterman; C P O'Brien
Journal:  Arch Gen Psychiatry       Date:  1997-08

10.  Differences in Substance Abuse Counselors' Knowledge of Tobacco Cessation Medication Effectiveness: 2002-2008.

Authors:  Tanja C Rothrauff; Amanda J Abraham; Paul M Roman
Journal:  J Drug Issues       Date:  2011-01
View more
  9 in total

1.  Counselor Attitudes Toward Contingency Management for Substance Use Disorder: Effectiveness, Acceptability, and Endorsement of Incentives for Treatment Attendance and Abstinence.

Authors:  Lydia Aletraris; Jeff S Shelton; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2015-05-07

2.  Climate for innovation, 12-step orientation, and tobacco cessation treatment.

Authors:  Jessica L Muilenburg; Tanja C Laschober; Lillian T Eby
Journal:  J Subst Abuse Treat       Date:  2013-11-12

3.  Service delivery and pharmacotherapy for alcohol use disorder in the era of health reform: Data from a national sample of treatment organizations.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  Subst Abus       Date:  2015-04-20       Impact factor: 3.716

4.  Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV.

Authors:  Benjamin J Oldfield; Kathleen A McGinnis; E Jennifer Edelman; Emily C Williams; Adam J Gordon; Kathleen Akgün; Stephen Crystal; Lynn E Fiellin; Julie R Gaither; Joseph L Goulet; P Todd Korthuis; Brandon D L Marshall; Amy C Justice; Kendall Bryant; David A Fiellin; Kevin L Kraemer
Journal:  J Subst Abuse Treat       Date:  2019-11-06

Review 5.  Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.

Authors:  Elizabeth M Oliva; Natalya C Maisel; Adam J Gordon; Alex H S Harris
Journal:  Curr Psychiatry Rep       Date:  2011-10       Impact factor: 5.285

6.  Impact of research network participation on the adoption of buprenorphine for substance abuse treatment.

Authors:  Traci R Rieckmann; Amanda J Abraham; Anne E Kovas; Bentson H McFarland; Paul M Roman
Journal:  Addict Behav       Date:  2014-02-07       Impact factor: 3.913

7.  The Use of Exposure-Based Treatment Among Individuals With PTSD and Co-occurring Substance Use Disorders: Clinical Considerations.

Authors:  Therese K Killeen; Sudie E Back; Kathleen T Brady
Journal:  J Dual Diagn       Date:  2011-10-01

8.  Views about responsibility for alcohol addiction and negative evaluations of naltrexone.

Authors:  Rebecca A Johnson; Jonathan M Lukens; Jonathan W Kole; Dominic A Sisti
Journal:  Subst Abuse Treat Prev Policy       Date:  2015-03-08

Review 9.  Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA.

Authors:  Amanda J Abraham; Christina M Andrews; Samantha J Harris; Peter D Friedmann
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.